13F Holdings
中文EN

ACB AURORA CANNABIS INC IFRS

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1683541 · Reporting currency CAD · Fiscal year ends 03/31

Financial factors as of 2022-06-30 (FY2022), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-9.8%
TTM net income YoY-148.2%
TTM EPS YoY-94.9%
Revenue 3-yr CAGR-3.4%
Net income 3-yr CAGR—

Margins

Gross margin9.6%
Operating margin-104.6%
Net margin-776.0%
FCF margin-64.4%
EBITDA margin-82.6%

Returns

ROE-127.3%
ROA-93.1%
ROIC (approx.)-19.9%
Asset turnover0.12x

Leverage & solvency

Liabilities / assets38.9%
Debt / equity0.00x
Current ratio5.69x
Interest coverage-3.22x

Cash quality & payout

Operating cash flow / net income0.06x
Accruals ratio-87.1%
Payout ratio—
Capex / revenue14.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CAD FY2025*2025-03-31FY2024*2024-03-31FY20222022-06-30FY20212021-06-30FY20202020-06-30
Income statement
Revenue343.29M269.64M221.34M245.25M268.70M
Gross profit187.61M131.73M21.23M-21.56M-19.93M
R&D expense3.68M3.57M10.39M11.45M26.03M
SG&A expense97.26M91.33M175.24M174.63M196.36M
Operating income4.95M-45.10M-231.45M-282.82M-465.78M
Interest expense8.42M13.80M71.81M66.44M76.11M
Pretax income20.38M-57.64M-1.72B-699.80M-3.34B
Income tax4.62M-554,000-2.14M-6.32M-82.23M
Net income1.59M-69.33M-1.72B-692.01M-3.28B
EBITDA14.03M-33.12M-182.85M-233.64M-398.21M
EPS (basic)0.04-1.52-7.99-4.10-33.93
EPS (diluted)0.04-1.52-7.99-4.10-33.93
Weighted avg. shares (diluted)55.62M43.22M———
Balance sheet
Cash & equivalents137.92M136.09M437.81M421.46M162.18M
Short-term investments554,0004.04M———
Receivables42.47M45.41M46.99M56.26M54.11M
Inventory187.93M143.60M116.10M117.47M135.88M
Current assets478.33M426.61M745.12M665.89M417.51M
PP&E, netmay include right-of-use assets (IFRS)268.11M294.32M233.47M606.09M946.38M
Goodwill43.87M43.18M0887.74M927.88M
Intangibles45.16M40.85M70.70M367.45M412.27M
Total assets852.67M838.67M1.08B2.60B2.78B
Current liabilities110.86M124.62M130.86M116.38M272.26M
Short-term debt2.30M52.36M00113.92M
Long-term debt40.19M4.90M0—83.70M
Total debt42.49M57.26M0—197.62M
Total liabilities244.07M236.80M422.00M567.03M656.70M
Shareholders' equity567.17M559.77M661.84M2.04B2.15B
Net debt-95.43M-78.84M-437.81M—35.44M
Cash flow statement
Operating cash flow16.00M-68.51M-110.27M-210.58M-342.14M
Capital expenditure——32.21M53.08M—
Free cash flow——-142.48M-263.66M—
Investing cash flow-14.33M-3.36M-36.17M-26.91M-245.43M
Financing cash flow-116,000-47.92M147.78M521.95M582.56M
Depreciation & amortization9.08M11.98M48.60M49.17M67.57M
Stock-based compensation11.52M12.72M13.76M20.24M59.18M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.